A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QMF149 in Japanese Patients With Asthma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Indacaterol/mometasone (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 30 Jan 2018 Planned End Date changed from 8 Feb 2019 to 22 Feb 2019.
- 30 Jan 2018 Planned primary completion date changed from 23 Jul 2018 to 20 Jul 2018.
- 18 Jan 2018 Status changed from recruiting to active, no longer recruiting.